Table 2.

Schedule of evaluations

PLM-MDD Schedule of Evaluations	Screening and Webinar	MDD Forum	User Experience	Screening	Baseline	Weeks 1–5	Week 6	Weeks 7–11	Week 12	Weeks 13–17	Week 18	Weeks 19–23	Week 24
						+6 days	+6 days	+6 days	+6 days	+6 days	+6 days	+6 days	+10 days
Qualitative Component
Screening and webinar invites	X
Webinar	X
Screening and invites	X
Qualitative consent		X	X
Q&A forum		X
Useability and functionality insights			X
Quantitative Component
Background and Insights
Screening and invite emails				X
Consent					X
MDD diagnosis confirmation					Xa
Demographics (age, sex, race, ethnicity, weight, height, employment status, insurance class)					X
Comorbidities					X
Antidepressant treatment experience					X
Characterization of symptom experience importance and patterns					X				X				X
Patient experiences: goals and HCP communication					X				X				X
Current antidepressant medication					X				X				X
PLM Web-Based Assessments
PHQ-9				X			X		X		X		X
Baseline reflection on current depression status					X
PGI-I									X				X
Q-LES-Q-SF					X				X				X
PDQ-D5					X				X				X
WHO-5					X				X				X
Emotional blunting questions					X				X				X
SHAPS questions					X				X				X
CD-RISC-10					X				X				X
Goal setting/tracking questions					X				X				X
Goal setting					X				X
Goal attainment tracking						X	X	X	X	X	X	X	X
Goal attainment scale for depression									X				X

^a6 weeks for MDD confirmation

CD-RISC-10 10-Item Conner-Davidson Resilience Scale, HCP healthcare provider, MDD major depressive disorder, PDQ-D5 5-item Perceived Deficits Questionnaire–Depression, PGI-I Patient Global Impression of Improvement, PHQ-9 9-item Patient Health Questionnaire, PLM PatientsLikeMe, Q&A question-and-answer, Q-LES-Q-SF Quality of Life Enjoyment and Satisfaction Questionnaire–Short Form, SHAPS Snaith-Hamilton Pleasure Scale, WHO-5 5-item World Health Organization Well-being Index